Immunovant, Inc.IMVTNASDAQ

Revenue (LTM)

Net Income (LTM)

$-414M

-59.6% YoY

Free Cash Flow

$-377M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.4B)

Unprofitable

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Revenue	0	0	0	0	0
Gross Profit	0	0	0	0	0
Operating Income	-108	-156↓44.3%	-208↓33.5%	-270↓29.7%	-438↓62.2%
Net Income	-107	-157↓45.9%	-211↓34.6%	-259↓22.9%	-414↓59.6%
EBITDA	-108	-156↓44.3%	-208↓33.5%	-270↓29.7%	-438↓62.2%
EPS Diluted	-1.22	-1.43↓17.2%	-1.71↓19.6%	-1.88↓9.9%	-2.73↓45.2%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Cash & Equivalents	400	494↑23.4%	377↓23.8%	635↑68.7%	714↑12.4%
Total Current Assets	409	513↑25.4%	404↓21.2%	666↑64.7%	768↑15.3%
Total Assets	412	516↑25.0%	406↓21.3%	667↑64.3%	776↑16.4%
Total Current Liabilities	19	45↑137.2%	43↓2.7%	49↑12.3%	69↑41.5%
Total Liabilities	21	46↑117.7%	43↓5.2%	49↑12.9%	69↑40.5%
Total Equity	391	470↑20.0%	362↓22.8%	618↑70.4%	707↑14.5%
Total Debt	3	2↓30.8%	1↓48.4%	0↓88.7%	0↓29.0%
Net Debt	-397	-491↓23.9%	-375↑23.6%	-635↓69.3%	-714↓12.4%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Operating Cash Flow	-83	-106↓27.3%	-188↓77.4%	-214↓13.8%	-376↓75.5%
Capital Expenditure	-0	-0↓21.0%	-0↑22.4%	-0↓82.7%	-1↓110.8%
Free Cash Flow	-84	-106↓27.3%	-188↓77.1%	-215↓13.9%	-377↓75.5%
Stock-Based Comp	0	34	32↓5.7%	41↑27.3%	49↑20.4%
Net Change in Cash	300	94↓68.7%	-117↓225.2%	259↑320.7%	79↓69.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance